Selected Publications

A Barz Leahy, KJ Devine, Y Li, H Liu, RM Myers, AM DiNofia, L Wray, SR Rheingold, C Callahan, D Baniewicz, M Patino, H Newman, SP Hunger, SA Grupp, DM Barrett, SL Maude: Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood April 2022.

RM Myers, A Taraseviciute, SM Steinberg, AJ Lamble, J Sheppard, B Yates, AE Kovach, B Wood, MJ Borowitz, M Stetler-Stevenson, CM Yuan, V Pillai, T Foley, P Chung, L Chen, DW Lee, C Annesley, AM DiNofia, SA Grupp, S John, D Bhojwani, PA Brown, TW Laetsch, L Gore, RA Gardner, SR Rheingold, MA Pulsipher, NN Shah: Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. Journal of Clinical Oncology March 2022.

KO McNerney, AM DiNofia, DT Teachey, SA Grupp, SL Maude: Potential Role of IFN inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discovery March 2022.

BJ Lerman, Y Li, H Liu, RM Myers, K Devine, C Callahan, D Baniewicz, S Kaduake, AM DiNofia, SR Rheingold, L Wray, R Aplenc, SA Grupp, SL Maude, A Barz Leahy: Completed versus incomplete hematologic recovery after CAR T cell therapy: implications for relapse free survival and overall survival in pediatric and young adult patients with relapse/refractory B-ALL. Poster Presentation at American Society of Hematology Meeting and Exposition. Atlanta, GA Dec 2021.

AB Leahy, H Newman, Y Li, H Liu, R Myers, AM DiNofia, JG Dolan, C Callahan, D Baniewicz, K Devine, L Wray, R Aplenc, CH June, SA Grupp, SR Rheingold, SL Maude: CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukemia; a post-hoc analysis of pool data from five clinical trials. The Lancet Haematology October 2021.

RM Myers, Y Li, AB Leahy, DM Barrett, DT Teachey, C Callahan, CC Fasano, SR Rheingold, AM DiNofia, L Wray, R Aplenc, D Baniewicz, H Liu, PA Shaw, E Pequignot, KD Getz, JL Brogdon, AD Fesnak, DL Siegel, MM Davis, C Bartoszek, SF Lacey, EO Hexner, A Chew, GB Wertheim, BL Levine, CH June, SA Grupp, SL Maude: Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naïve and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. Journal of Clinical Onclolgy September 2021.

SJ Si Lim, SA Grupp, AM DiNofia: Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer June 2021 Notes: doi: 10.1002/pbc.29123. Online ahead of print.

AM DiNofia, SA Grupp: Will allogeneic CAR T cells for CD19 + malignancies take autologous CAR T cells 'off the shelf'? Nature Reviews Clinical Oncology 18(4): 195-196, Apr 2021.

S Kadauke, RM Myers, Y Li, R Aplenc, D Baniewicz, DM Barrett, A Barz Leahy, C Callahan, JG Dolan, JC Fitzgerald, W Gladney, SF Lacey, H Liu, SL Maude, R McGuire, LS Motley, DT Teachey, GB Wertheim, L Wray, AM DiNofia, SA Grupp: Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. Journal of Clinical Oncology 39(8): 920-930, Mar 2021.

C Diorio, PA Shaw, E Pequignot, A Orlenko, F Chen, R Aplenc, DM Barrett, H Bassiri, E Behrens, AM DiNofia, V Gonzalez, N Koterba, BL Levine, SL Maude, NJ Meyer, JH Moore, M Paessler, DL Porter, JL Bush, DL Siegel, MM Davis, D Zhang, CH June, SA Grupp, JJ Melenhorst, SF Lacey, SL Weiss, DT Teachey: Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances 4(20): 5174-5183, Oct 2020.